Oncology Institute, Inc. Income Statement
TOI|5 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Oncology Institute, Inc. reported $393M in revenue and $65M in net loss for FY2025. Revenue has grown at a 20.4% compound annual rate over the past 4 years.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $393.4M | $324.2M | $252.5M | $203.0M | $187.5M |
| SG&A Expense | $107.8M | $113.9M | $119.7M | $83.4M | $41.9M |
| Operating Income | -$60.1M | -$77.0M | -$82.0M | -$45.9M | -$8.2M |
| Interest Expense | - | - | -$4.1M | -$320.0K | $347.0K |
| Income Tax | $0 | -$36.0K | -$243.0K | -$671.0K | -$493.0K |
| Net Income | -$64.7M | -$83.1M | $152.0K | -$10.9M | -$14.3M |
| EPS (Basic) | -$0.71 | -$0.92 | $0.00 | -$0.16 | -$0.24 |
| EPS (Diluted) | -$0.71 | -$0.92 | -$0.21 | -$0.16 | -$0.24 |
| Shares Outstanding | 75.7M | 74.1M | 73.3M | 73.2M | 73.2M |
| Operating Margin | -15.3% | -23.8% | -32.5% | -22.6% | -4.4% |
| Profit Margin | -16.4% | -25.6% | 0.1% | -5.4% | -7.6% |